TY - JOUR
T1 - Improving management of diabetic kidney disease
T2 - will GLP-1 receptor agonists have a role?
AU - Bellary, Srikanth
AU - Tahrani, Abd
AU - Barnett, Anthony H.
PY - 2020/9/21
Y1 - 2020/9/21
N2 - Kidney disease affects around 40% of people with type 2 diabetes and is a leading cause of morbidity and mortality. 1 Management of diabetic kidney disease has traditionally focused on tight glycaemic control (in the early stages) and blood pressure control (with agents that inhibit the renin–angiotensin system). 1 Despite this, most patients with diabetic kidney disease experience a gradual decline in kidney function, eventually progressing to end-stage kidney disease and an increased risk of cardiovascular events and mortality. Glucagon-like peptide-1 (GLP-1) receptor agonists are established treatments for type 2 diabetes that, in addition to lowering glucose, are associated with weight loss, lowering of blood pressure, and cardioprotection. 2 There is a lack of clarity, however, on the long-term benefits of GLP-1 receptor agonist therapy in patients with diabetic kidney disease, particularly in relation to glomerular function.
AB - Kidney disease affects around 40% of people with type 2 diabetes and is a leading cause of morbidity and mortality. 1 Management of diabetic kidney disease has traditionally focused on tight glycaemic control (in the early stages) and blood pressure control (with agents that inhibit the renin–angiotensin system). 1 Despite this, most patients with diabetic kidney disease experience a gradual decline in kidney function, eventually progressing to end-stage kidney disease and an increased risk of cardiovascular events and mortality. Glucagon-like peptide-1 (GLP-1) receptor agonists are established treatments for type 2 diabetes that, in addition to lowering glucose, are associated with weight loss, lowering of blood pressure, and cardioprotection. 2 There is a lack of clarity, however, on the long-term benefits of GLP-1 receptor agonist therapy in patients with diabetic kidney disease, particularly in relation to glomerular function.
UR - http://www.scopus.com/inward/record.url?scp=85092464221&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(20)30301-6
DO - 10.1016/S2213-8587(20)30301-6
M3 - Comment/debate
SN - 2213-8587
VL - 8
SP - 870
EP - 871
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 11
ER -